Related references
Note: Only part of the references are listed.The Transition From Rome III to Rome IV Irritable Bowel Syndrome: What We Gain and Lose
Andrea Shin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study
Ami D. Sperber et al.
GASTROENTEROLOGY (2021)
Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom
Olafur S. Palsson et al.
GASTROENTEROLOGY (2020)
AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders
Grace L. Su et al.
GASTROENTEROLOGY (2020)
AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D)
Walter Smalley et al.
GASTROENTEROLOGY (2019)
AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D)
Alonso Carrasco-Labra et al.
GASTROENTEROLOGY (2019)
Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut - Brain Interaction): A Rome Foundation Working Team Report
Douglas A. Drossman et al.
GASTROENTEROLOGY (2018)
Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem
Asa Frandemark et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Development of the Diary for Irritable Bowel Syndrome Symptoms to Assess Treatment Benefit in Clinical Trials: Foundational Qualitative Research
Sheri E. Fehnel et al.
VALUE IN HEALTH (2017)
Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial
Brooks D. Cash et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome
Anthony Lembo et al.
GASTROENTEROLOGY (2016)
Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction INTRODUCTION
Douglas A. Drossman et al.
GASTROENTEROLOGY (2016)
Development and Validation of the Rome IV Diagnostic Questionnaire for Adults
Olafur S. Palsson et al.
GASTROENTEROLOGY (2016)
Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation
Prashant Singh et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials
P. Schoenfeld et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
American Gastroenterological Association Institute Technical Review on the Pharmacological Management of Irritable Bowel Syndrome
Lin Chang et al.
GASTROENTEROLOGY (2014)
American Gastroenterological Association Institute Guideline on the Pharmacological Management of Irritable Bowel Syndrome
David S. Weinberg et al.
GASTROENTEROLOGY (2014)
The AGA Institute Process for Developing Clinical Practice Guidelines Part One: Grading the Evidence
Shahnaz Sultan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Eluxadoline Benefits Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 Study
Leonard S. Dove et al.
GASTROENTEROLOGY (2013)
A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program
Kenneth Tong et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2013)
Modulation of gastrointestinal function by MuDelta, a mixed μ opioid receptor agonist/μ opioid receptor antagonist
P. R. Wade et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Rebecca M. Lovell et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Quality of Life in Patients With Irritable Bowel Syndrome
Hubert Moennikes
JOURNAL OF CLINICAL GASTROENTEROLOGY (2011)
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation.
Mark Pimentel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Citalopram Provides Little or No Benefit in Nondepressed Patients With Irritable Bowel Syndrome
Uri Ladabaum et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
A Double-Blind, Randomized, Placebo-Controlled Trial of Paroxetine Controlled-Release in Irritable Bowel Syndrome
Prakash S. Masand et al.
PSYCHOSOMATICS (2009)
Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist:: a pilot study
J. M. Jarcho et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome
H. Vahedi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Psychotropic agents in functional gastrointestinal disorders
Madhusudan Grover et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response
Anthony Lembo et al.
GASTROENTEROLOGY (2008)
Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial
Nicholas J. Talley et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS
Richard Krause et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment
Douglas Drossman et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome:: Baseline results from LOGIC (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study
Pierre Pare et al.
CLINICAL THERAPEUTICS (2006)
A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome
J. Tack et al.
GUT (2006)
Functional bowel disorders
George F. Longstreth et al.
GASTROENTEROLOGY (2006)
Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact
APS Hungin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS
L Chang et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome
WD Chey et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: A double-blind, placebo-controlled trial
G Tabas et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects
APS Hungin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome
M Camilleri et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Share Paper
